Lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-02. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
=== Genetics === Two-thirds of families with a history of type 2 diabetes report more than one family member having MASLD. There is a higher risk of fibrosis for family members where someone was diagnosed with MASH. Asian populations are more susceptible to metabolic syndrome and MASLD than their Western counterparts. Hispanic persons have a higher prevalence of MASLD than white individuals, whereas the lowest prevalence is observed in black individuals. MASLD is twice as prevalent in men as in women, which might be explained by lower levels of estrogen in men. Genetic variations in two genes are associated with MASLD: non-synonymous single-nucleotide polymorphisms (SNPs) in PNPLA3 and TM6SF2. Both correlate with MASLD presence and severity, but their roles for diagnosis remain unclear. Although MASLD has a genetic component, the American Association for the Study of Liver Diseases (AASLD) does not recommend screening family members as there is not enough confirmation of heritability, although there is some evidence from familial aggregation and twin studies.
== The Chemical Basis of Growth and Senescence (1923) == In between 1916 and 1920 Robertson published a series of 16 papers in the Journal of Biological Chemistry under the title Experimental Studies on Growth. The papers became the foundation of his (1923) textbook, The Chemical Basis of Growth and Senescence (BR.39): a work that examined the "self-accelerated" natural processes of growth and aging in plants, animals, and humans (as they were understood at that time). Using mathematical principles, Robertson employed an S-Curve (a.k.a. 'sigmoid curve') (p.5) to demonstrate both the "autokinetic phase" of a "self-accelerated" growth process, "during which the rate of growth is continuously increasing" (p.4), and its "autostatic phase", "during which the rate of growth is decreasing" (p.4). Drawing an analogy to the autocatalyzed chemical reactions of Wilhelm Ostwald (father of his Berkeley colleague Wolfgang Ostwald), Robertson referred to these "self-accelerated" processes as being "autocatalyzed" (p.6). As Lee and Hanson observed (in 1947), "[Robertson's] theory of autocatalytic control over growth ... has been variously rejected, acknowledged and accepted by investigators" (RL.1, p.53).
The main role of the tissue factor (TF) pathway is to generate a "thrombin burst", a process by which thrombin, the most important constituent of the coagulation cascade in terms of its feedback activation roles, is released very rapidly. FVIIa circulates in a higher amount than any other activated coagulation factor. The process includes the following steps:
Sources: en.wikipedia.org
Most of the pieces made today, with turquoise usually roughly polished into irregular cabochons set simply in silver, are meant for inexpensive export to Western markets and are probably not accurate representations of the original style. The Ancient Egyptian use of turquoise stretches back as far as the First Dynasty and possibly earlier; however, probably the most well-known pieces incorporating the gem are those recovered from Tutankhamun's tomb, most notably the Pharaoh's iconic burial mask which was liberally inlaid with the stone. It also adorned rings and great sweeping necklaces called pectorals. Set in gold, the gem was fashioned into beads, used as inlay, and often carved in a scarab motif, accompanied by carnelian, lapis lazuli, and in later pieces, coloured glass. Turquoise, associated with the goddess Hathor, was so liked by the Ancient Egyptians that it became (arguably) the first gemstone to be imitated, the fair structure created by an artificial glazed ceramic product known as faience. The French conducted archaeological excavations of Egypt from the mid-19th century through the early 20th. These excavations, including that of Tutankhamun's tomb, created great public interest in the western world, subsequently influencing jewellery, architecture, and art of the time. Turquoise, already favoured for its pastel shades since around 1810, was a staple of Egyptian Revival pieces.
In 1999 the laboratory of Prof. Dr. Ben L. Feringa at the University of Groningen, The Netherlands, reported the creation of a unidirectional molecular rotor. Their 360° molecular motor system consists of a bis-helicene connected by an alkene double bond displaying axial chirality and having two stereocenters. One cycle of unidirectional rotation takes 4 reaction steps. The first step is a low temperature endothermic photoisomerization of the trans (P,P) isomer 1 to the cis (M,M) 2 where P stands for the right-handed helix and M for the left-handed helix. In this process, the two axial methyl groups are converted into two less sterically favorable equatorial methyl groups. By increasing the temperature to 20 °C these methyl groups convert back exothermally to the (P,P) cis axial groups (3) in a helix inversion. Because the axial isomer is more stable than the equatorial isomer, reverse rotation is blocked. A second photoisomerization converts (P,P) cis 3 into (M,M) trans 4, again with accompanying formation of sterically unfavorable equatorial methyl groups. A thermal isomerization process at 60 °C closes the 360° cycle back to the axial positions.
The Emperor Naruhito and Empress Masako of Japan begin a three-day state visit to the United Kingdom by meeting the King and Queen Camilla. 26 June The media is allowed to report that Constance Marten and Mark Gordon were convicted of concealing the birth of a child and preventing the course of justice after reporting restrictions are lifted. The pair also face a retrial for manslaughter provisionally scheduled to begin in March 2025 and will remain in custody until then. An inquest jury finds that failures "across multiple agencies" contributed to the death of Zara Aleena, who was sexually assaulted and murdered in June 2022 as she walked home from a night out. 2024 United Kingdom general election betting scandal: Alex Cole-Hamilton, leader of the Scottish Liberal Democrats, admits to placing bets on Scottish Liberal Democrat election candidates, but says he did not place bets on the date of the election itself. The Sun reports that Sir Philip Davies, the Conservative candidate for Shipley, allegedly placed an £8,000 bet on whether he would lose his seat at the election, which has a majority of 6,242. 27 June The first death from the E. coli outbreak is reported, as the number of confirmed cases reaches 275. The Metropolitan Police says that at least seven police officers are now being investigated for placing bets on the date of the general election. 28 June Revised data from the Office for National Statistics shows the UK economy grew by 0.7% in the first three months of 2024 as the UK emerged from a recession; the figures are slightly better than the original forecast.
== History == The Roman anatomist Galen commented on Hippocrates' work, classifying teeth as bones, noting their distinct characteristics compared to other bones. He was the first to discover nerves in teeth and identified seven cranial nerves in his research.
Sources: en.wikipedia.org
== Use on farms == From 2000 to 2005, the US Department of Agriculture National Agricultural Statistics Service survey of dairy producers found that about 17% of producers used rBST. The 2010 USDA National Agricultural Statistics Service survey of Wisconsin farms found that about 18% of dairy farms used rBST and 56% of dairy cows were given rBST.
{\displaystyle {\begin{aligned}{\text{triglyceride}}+{\ce {H2O}}&\longrightarrow {\text{fatty acid}}+{\text{diacylglycerol}}\\[4pt]{\text{diacylglycerol}}+{\ce {H2O}}&\longrightarrow {\text{fatty acid}}+{\text{monacylglycerol}}\\[4pt]{\text{monacylglycerol}}+{\ce {H2O}}&\longrightarrow {\text{fatty acid}}+{\text{glycerol}}\end{aligned}}}
== Treatment == Prednisone is usual drug for PMR, and treatment frequently lasts for more than a year. If the patient does not experience dramatic improvement after three days of 10–20 mg oral prednisone per day, the diagnosis should be reconsidered. Sometimes relief of symptoms occurs in only several hours. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen are ineffective in the initial treatment of PMR, but they may be used in conjunction with the maintenance dose of corticosteroid. Along with medical treatment, patients are encouraged to exercise and eat healthily, helping to maintain a strong immune system and build strong muscles and bones. A diet of fruits, vegetables, whole grains, and low-fat meat and dairy products, avoiding foods with high levels of refined sugars and salt is recommended. Research in the UK has also suggested that people with polymyalgia rheumatica would benefit from a falls assessment when first diagnosed, and regular treatment reviews.
These frequent long treatments are often done at home while sleeping, but home dialysis is a flexible modality and schedules can be changed day to day, week to week. In general, studies show that both increased treatment length and frequency are clinically beneficial. Hemo-dialysis was one of the most common procedures performed in U.S. hospitals in 2011, occurring in 909,000 stays (a rate of 29 stays per 10,000 population).
=== Elements regarding the consideration of gender in medicine === Efforts to incorporate gender into medical research began in the late 1980s, primarily in the United States. In 1995, the World Health Organization (WHO) established the Department of Gender and Women's Health. Several European countries followed in the early 2000s by creating research bodies focused on gender in medicine. In France, the "Gender and Health Research" group was created at Inserm in 2013. Public institutions such as French National Public Health Agency and the Haute Autorité de Santé (HAS) have since addressed gender disparities in research and treatment.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.